apitegromab tirzepatide Apitegromab, a selective antimyostatin monoclonal antibody targeting muscle preservation, added to reduced muscle loss by ~55% over 24 weeks without affecting overall weight loss in the phase 2 EMBRAZE trial. https://t.co/jDqTipQrZa Tirzepatide outperformed semaglutide weight-loss drug
Pay in 4 interest-free payments of $5.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9




























